Provention Bio - About the company
Provention Bio is an acquired company based in Hunterdon (United States), founded in 2016 by Francisco Leon. It operates as a Developer of therapeutic solutions for treating immune-mediated diseases. Provention Bio has raised $28.5M in funding from Johnson & Johnson Innovation and T1D Fund. The company has 431 active competitors, including 139 funded and 117 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.
Company Details
Developer of therapeutic solutions for treating immune-mediated diseases, The company focused on developing investigational immunomodulatory therapies that may intercept and prevent immune-mediated diseases. The company develops a pipeline for autoimmune diseases, including type 1 diabetes, celiac disease, and lupus.
- Website
- proventionbio.com
- Email ID
- *****@proventionbio.com
- Phone Number
- +1 **********
- Registered Address
- 55 Broad Street, 2nd Floor Red Bank, NJ 07701
Key Metrics
Founded Year
2016
Location
Hunterdon, United States
Stage
Acquired
Total Funding
$28.5M in 3 rounds
Latest Funding Round
Investors
Ranked
88th among 431 active competitors
Employee Count
50 - 199 as on Mar 01, 2026
Exit Details
Acquired by Sanofi (Mar 13, 2023)
Legal entities associated with Provention Bio
Provention Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
PROVENTION BIO, INC. CIN: 6172593 , United States, Active | Oct 03, 2016 | - | 82 (As on Feb 28, 2022) | - |
Provention Bio's acquisition details
Provention Bio got acquired by Sanofi on Mar 13, 2023.
Click here to take a look at Provention Bio's acquisition in detail
Sign up to download Provention Bio's company profile
Provention Bio's funding and investors
Provention Bio has raised a total funding of $28.5M over 3 rounds. Its first funding round was on May 04, 2017. Its latest funding round was a Post IPO round on Feb 14, 2023 for $*****. 1 investor participated in its latest round. Provention Bio has 7 institutional investors.
Here is the list of recent funding rounds of Provention Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 14, 2023 | 2716901 | Post IPO | 4868212 | 9121579 | 2561914 | 4072024 |
Jul 07, 2022 | 1528429 | Post IPO | 9053144 | 1889172 | 7183366 | |
May 04, 2017 | 5281206 | Series A | 2204894 | 1269749 | 2342198 |
Access funding benchmarks and valuations. Sign up today!View details of Provention Bio's funding rounds and investors
Provention Bio's founders and board of directors
Founder? Claim ProfileThe founders of Provention Bio is Francisco Leon.
Here are the details of Provention Bio's key team members:
- Francisco Leon: Co-Founder of Provention Bio.
View details of Provention Bio's Founder profiles and Board Members
Provention Bio's employee count trend
Provention Bio has 50 - 199 employees as of Mar 26. Here is Provention Bio's employee count trend over the years:
Uncover Provention Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Provention Bio's Competitors and alternates
Top competitors of Provention Bio include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Provention Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
5th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
6th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
7th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 | |
8th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 68/100 | |
9th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
10th | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
88th | Provention Bio 2016, Hunterdon (United States), Acquired | Developer of therapeutic solutions for treating immune-mediated diseases | $28.5M | 43/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Provention Bio's competitors? Click here to see the top ones
Provention Bio's Investments and acquisitions
Provention Bio has made no investments or acquisitions yet.
Reports related to Provention Bio
Here is the latest report on Provention Bio's sector:
News related to Provention Bio
Filter this list•
•
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.GlobeNewswire•Apr 26, 2023•Sanofi, Provention Bio
•
Sanofi to get commercial control of RSV therapy nirsevimab in US, AstraZeneca to record $0.7B gainSeeking Alpha•Apr 11, 2023•AstraZeneca, Swedish Orphan Biovitrum, Sanofi, Provention Bio
•
Sanofi withdraws and refiles pre-merger notification, report form to acquire Provention BioSeeking Alpha•Apr 11, 2023•Sanofi, Provention Bio
•
•
•
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, XM, PRVB, SGENGlobeNewswire•Mar 16, 2023•Malvern Bank, Qualtrics, Provention Bio, Seattle Genetics
•
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVBBusiness Wire•Mar 14, 2023•Provention Bio, Kahn Swick & Foti
•
•
Sanofi signs deal to buy Provention Bio for $2.9 billionFusoes & Aquisicoes•Mar 14, 2023•Sanofi, Provention Bio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Provention Bio
Explore our recently published companies
- Stone - London based, 2017 founded, Unfunded company
- TechGraphx & Printing - Newark based, 1999 founded, Unfunded company
- Andrus Hospitality - United States based, 2016 founded, Unfunded company
- the travelers travel - Hayward based, Unfunded company
- Iotelinfotech - Unfunded company
- EB5 Marketplace - New York City based, 2012 founded, Unfunded company
